Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-04-2019 | Nephrectomy | Original Article – Clinical Oncology

Preoperative controlling nutritional status (CONUT) score as a novel immune-nutritional predictor of survival in non-metastatic clear cell renal cell carcinoma of ≤ 7 cm on preoperative imaging

Authors: Ahmed Elghiaty, Jongchan Kim, Won Sik Jang, Jee Soo Park, Ji Eun Heo, Koon Ho Rha, Young Deuk Choi, Won Sik Ham

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2019

Abstract

Purpose

This study aimed at investigating the prognostic value of Preoperative controlling nutritional status (CONUT) score in non-metastatic clear-cell renal cell carcinoma of ≤ 7 cm on preoperative imaging.

Methods

We retrospectively included 1046 among 1637 patients who underwent radical or partial nephrectomy for solid renal masses ≤ 7 cm (2005–2014) after excluding other pathology, conditions affecting CONUT score components, metastasis, regional lymphadenopathy, positive margin, and follow-up < 12 months. We defined high and low CONUT according to cut-off of (2). Multivariate Cox-regression analysis was used to predict factors affecting recurrence and survival. Kaplan–Meier curve was used for survival analysis.

Results

The median age and follow-up were 56 years and 63 months, respectively. 41 patients had recurrence (3.9%). CONUT was a predictor for recurrence-free, cancer-specific, and overall survival (HR 3.09, P = 0.003 and HR 4.66, P = 0.004 and HR 2.81, P = 0.003, respectively). A higher CONUT was significantly associated with worse 5 years recurrence-free (88.2% vs. 97.1%), cancer-specific (96.2% vs. 98.8%) and overall (90.9% vs. 96.5%) survival (log-rank, P = < 0.001, P = 0.006 and P = < 0.001, respectively).

Conclusions

The preoperative CONUT is an independent prognostic marker for survival after curative surgery for non-metastatic clear-cell renal cell carcinoma of ≤ 7 cm on preoperative imaging.

Arends J et al (2017) ESPEN guidelines on nutrition in cancer patients. Clin Nutr 36(1):11–48. https://doi.org/10.1016/j.clnu.2016.07.015 CrossRefPubMed

Cengiz O, Kocer B, Sürmeli S, Santicky MJ, Soran A (2006) Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monit 12(6):CR240–C247PubMed

Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474. https://doi.org/10.1245/s10434-010-0985-4 CrossRefPubMed

Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663CrossRefPubMed

Ignacio de Ulíbarri J et al (2005) CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp 20:38–45PubMed

Iseki Y et al (2015) Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer. PLoS one 10:e0132488. https://doi.org/10.1371/journal.pone.0132488 CrossRefPubMedPubMedCentral

Ishihara H, Kondo T, Omae K, Takagi T, Iizuka J, Kobayashi H, Tanabe K (2016) Sarcopenia and the modified Glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment. Target Oncol 11(5):605–617. https://doi.org/10.1007/s11523-016-0430-0 CrossRefPubMed

Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, Tanabe K (2017) Preoperative Controlling Nutritional Status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy. Urol Oncol 35(9):539.e9–539.e16. https://doi.org/10.1016/j.urolonc.2017.04.012 CrossRef

Jeon HG et al (2016) Preoperative Prognostic Nutritional Index is a significant predictor of survival in renal cell carcinoma patients undergoing nephrectomy. Ann Surg Oncol 23(1):321–327. https://doi.org/10.1245/s10434-015-4614-0 CrossRefPubMed

Kang HW et al (2018) Low preoperative serum cholesterol level is associated with aggressive pathologic features and poor cancer-specific survival in patients with surgically treated renal cell carcinoma. Int J Clin Oncol 23(1):142–150. https://doi.org/10.1007/s10147-017-1172-4 CrossRefPubMed

Karl A, Rittler P, Buchner A, Fradet V, Speer R, Walther S, Stief GC (2009) Prospective assessment of malnutrition in urologic patients. Urology 73:1072–1076. https://doi.org/10.1016/j.urology.2008.12.037 CrossRefPubMed

Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS (2004) Cachexia-like symptoms predict a worse prognosis in localized T1 renal cell carcinoma. J Urol 171:1810–1813. https://doi.org/10.1097/01.ju.0000121440.82581.d3 CrossRefPubMed

Ko K, Park YH, Lee JW, Ku JH, Kwak C, Kim HH (2013) Influence of nutritional deficiency on prognosis of renal cell carcinoma (RCC). BJU Int 112(6):775–780. https://doi.org/10.1111/bju.12275 CrossRefPubMed

Kunimura A et al (2017) Impact of nutritional assessment and Body Mass Index on cardiovascular outcomes in patients with stable coronary artery disease. Int J Cardiol 230:653–658. https://doi.org/10.1016/j.ijcard.2017.01.008 CrossRefPubMed

Kutikov A, Egleston BL, Wong YN, Uzzo RG (2010) Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 28:311–317. https://doi.org/10.1200/JCO.2009.22.4816 CrossRefPubMed

Liang RF, Li JH, Li M, Yang Y, Liu YH (2017) The prognostic role of controlling nutritional status scores in patients with solid tumors. Clin Chim Acta 474:155–158. https://doi.org/10.1016/j.cca.2017.09.021 CrossRefPubMed

Linehan WM, Ricketts CJ (2013) The metabolic basis of kidney cancer. Semin Cancer Biol 3(1):46–55. https://doi.org/10.1016/j.semcancer.2012.06.002 CrossRef

Lipschitz DA (1988) Protein-energy malnutrition. Hosp Pract (Off Ed) 23:87–99. https://doi.org/10.1080/21548331.1988.11703582 CrossRef

Llop JM et al (2001) Serum albumin as indicator of clinical evolution in patients on parenteral nutrition. Multivar Study Clin Nutr 20:77–81. https://doi.org/10.1054/clnu.2000.0159 CrossRef

Lucca I, de Martino M, Hofbauer SL, Zamani N, Shariat SF, Klatte T (2015) Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinoma. World J Urol 33(12):2045–2052. https://doi.org/10.1007/s00345-015-1559-7 CrossRefPubMed

Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444. https://doi.org/10.1038/nature07205 CrossRefPubMed

Mimatsu K, Fukino N, Ogasawara Y, Saino Y, Oida T (2017) Utility of inflammatory marker- and nutritional status-based prognostic factors for predicting the prognosis of stage IV gastric cancer patients undergoing non-curative surgery. Anticancer Res 37:4215–4222. https://doi.org/10.21873/anticanres.11812 CrossRefPubMed

Morgan T et al (2011) Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 59:923–928. https://doi.org/10.1016/j.eururo.2011.01.034 CrossRefPubMedPubMedCentral

Park YH, Baik KD, Lee YJ, Ku JH, Kim HH, Kwak C (2012) Late recurrence of renal cell carcinoma> 5 years after surgery: clinicopathological characteristics and prognosis. BJU Int 110:E553. https://doi.org/10.1111/j.1464-410X.2012.11246.x CrossRefPubMed

Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M (2012) Sarcopenic obesity: acritical appraisal of the current evidence. Clin Nutr 31:583–601. https://doi.org/10.1016/j.clnu.2012.06.010 CrossRefPubMed

Saroha S, Uzzo RG, Plimack ER, Ruth K, Al-Saleem T (2013) Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol 189:454–461. https://doi.org/10.1016/j.juro.2012.09.166 CrossRefPubMed

Shoji F et al (2017) The preoperative controlling nutritional status score predicts survival after curative surgery in patients with pathological stage I non-small cell lung cancer. Anticancer Res 37(2):741–747. https://doi.org/10.21873/anticanres.11372 CrossRefPubMed

Shuch B et al (2015) Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol 97:67–85. https://doi.org/10.1016/j.eururo.2014.04.029 CrossRef

Takamori S et al (2017) The controlling nutritional status score is a significant independent predictor of poor prognosis in patients with malignant pleural mesothelioma. Clin Lung Cancer 18:e303–e313. https://doi.org/10.1016/j.cllc.2017.01.008 CrossRefPubMed

Toyokawa T et al (2016) The pretreatment controlling nutritional status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. BMC Cancer 16(1):722. https://doi.org/10.1186/s12885-016-2696-0 CrossRefPubMedPubMedCentral

Title: Preoperative controlling nutritional status (CONUT) score as a novel immune-nutritional predictor of survival in non-metastatic clear cell renal cell carcinoma of ≤ 7 cm on preoperative imaging
Authors: Ahmed Elghiaty
Jongchan Kim
Won Sik Jang
Jee Soo Park
Ji Eun Heo
Koon Ho Rha
Young Deuk Choi
Won Sik Ham
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Keywords: Nephrectomy
Kidney Cancer
Kidney Cancer
Nephrectomy
Kidney Cancer
Nephrectomy
Published in: Journal of Cancer Research and Clinical Oncology / Issue 4/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02846-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2019

Regorafenib in patients with recurrent high-grade astrocytoma

Expression of Syk and MAP4 proteins in ovarian cancer

Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma

Computer-assisted medical image classification for early diagnosis of oral cancer employing deep learning algorithm

Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers

Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials